Media Coverage

As the Biden administration works to accelerate the U.S. coronavirus vaccine rollout, it could soon have a new tool: A single-dose vaccine that can survive up to three months in an ordinary refrigerator. Manufacturer Johnson & Johnson released data on January 29 showing that its single-dose version provided strong protection against COVID-19. On February 24, the U.S. Food and Drug Administration released an analysis of Johnson & Johnson’s vaccine confirming that it is safe and effective, and on February 26 a review committee within the agency recommended that the FDA authorize the shot for emergency use.

Millions of Americans are not getting their second dose of the coronavirus vaccine within the recommended time period for ensuring optimal protection from COVID-19, according to a CBS MoneyWatch review of the latest data from the U.S. Centers for Disease Control and Prevention. As of Wednesday, just over 2.8 million Americans who had received their first shot — nearly 12% of those vaccinated — had not gotten their second dose within the 28-day interval prescribed for Moderna’s vaccine, one of two approved for use in the U.S. The other vaccine, jointly produced by Pfizer and Germany’s BioNTech, is supposed to be administered 21 days after getting a first dose.

The U.S. government has invested billions of dollars in manufacturing, used a wartime act dozens of times to boost supplies and yet there is still not enough COVID-19 vaccine on the way to meet demand—or even the government’s own goals for national immunization. President Joe Biden, in remarks at the National Institutes of Health in Feburary, said the nation is “now on track to have enough supply for 300 million Americans by the end of July.” But at the current rate of production, Pfizer and Moderna will miss their targets of providing at least 100 million doses each by the end of March, let alone 200 million more doses each has promised by July.

First, I would like to thank you for your excellent coverage of the COVID-19 in our region and beyond. Having data transparency and information now are imperative as we wage the battle against the coronavirus. In the article, ”COVID-19 cases spike at UMass,” on Saturday, Feb. 6, it is stated that the state of Massachusetts has received 896,300 doses of the Moderna and Pfizer vaccines, and 681, 472 doses have been administered. However, the CDC reports on the same date that Massachusetts has received 1,229,075 doses and has administered 652,929. It is understandable that there may be some delays in updating the reports. It appears that over 350,000 doses are somehow unaccounted for in the state of Massachusetts.

Officials with Giant Eagle say that all phone appointments have been filled. The federal government provided more vaccines to Pennsylvania this week than since the rollout began in December. That’s allowed for mass clinics such as the one planned at Heinz Field with the Pittsburgh Steelers and Giant Eagle next week; but there are still thousands in Phase 1a trying to get the vaccine that have been left in the dark. “When a vaccine clinic pops up that doesn’t have a 65-and-older restriction and nothing else, I’m always looking to see what we can do,” said Larry Barasch, who is in Phase 1a, but just under 65 years old. “I actually kept checking at 10 o’clock, 11 o’clock, midnight, and then went to sleep. I got up at 3 a.m. and had three computers on and kept tracking, but there was always nothing available.”